Letter to the EditorIdentification of a new HCV subtype 6xi among chronic hepatitis C patients in Yunnan, China
Section snippets
Declaration of Competing Interest
The authors declare no competing financial interests.
Acknowledgments
We thank the members of the clinical laboratory in the First People's Hospital of Yunnan Province for the clinical data and sample collection.
Funding
This work was supported by the Major special projects and key R & D projects in Yunnan Province (2019ZF004), the Key projects of Yunnan applied basic research plan (2019FA005), the Reserve Talents Project for Young and Middle-Aged Academic and Technical Leaders of Yunnan Province (2019HB012), the Science and Technology Department of Yunnan Province (2018DG010), Youth Talent Program of Yunnan “Ten-thousand Talents Program” (YNWR-QNBJ-2018-054), and the Medical Leading Talent Program of Yunnan
References (10)
- et al.
Hepatitis C virus infection in children and adolescents
Lancet Gastroenterol Hepatol
(2019) - et al.
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
J Hepatol
(2018) - et al.
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018
Drug Resist Updat
(2018) - et al.
Molecular evolution of hepatitis C virus in China: a nationwide study
Virology
(2018) - et al.
Consensus recommendations for resistance testing in the management of chronic hepatitis c virus infection: Public Health England HCV Resistance Group
J Infect
(2019)
There are more references available in the full text version of this article.
Cited by (0)
- 1
These authors contributed equally in this work.
© 2019 Published by Elsevier Ltd on behalf of The British Infection Association.